MRVL Plunges 36% in a Month: Should You Buy, Sell or Hold the Stock?

Marvell shares fell 35.9% in a month, underperforming the semiconductor industry’s 22% decline and the technology sector’s 14.1%; its 8.58x forward P/S also remains well above the industry’s 3.08x. Against that weakness, fiscal Q2 2027 revenue rose 37% year over year to $2.74 billion, and management raised its fiscal 2027 revenue-growth outlook to about 45% (roughly $12 billion). Marvell’s proposed $115 billion all-stock acquisition of Lumentum could broaden its AI connectivity portfolio, but raises valuation, dilution, integration and execution concerns; Zacks rates MRVL #2 (Buy).

Analysis

The key issue is not whether optical connectivity fits Marvell’s portfolio; it is whether the deal converts into durable customer wins and earnings without weakening returns through dilution or integration costs. An all-stock structure shifts much of the risk to MRVL holders: the fixed exchange ratio leaves them exposed to share issuance and any decline in MRVL before closing, while Lumentum holders participate in that downside. Treat the stated transaction value and terms as provisional until confirmed in definitive filings; verify pro forma share count, closing conditions, and accretion/dilution assumptions.

Strategically, combining silicon, DSPs, switching, and photonics could improve solution breadth, but may also create customer-neutrality concerns if cloud customers view an integrated supplier as less attractive than best-of-breed vendors. That could benefit Broadcom or Coherent if customers diversify sourcing. Near term (days), the sharp selloff may invite reflexive dip-buying, but the premium sales multiple leaves little cushion if AI spending expectations reset. Over 1–3 months, deal documentation, regulatory progress, and margin/guidance evidence matter more than portfolio-combination claims. Over 6–18 months, the thesis depends on design wins and profitable ramps—not revenue growth alone. Contrarian point: the selloff may be pricing both AI demand risk and deal dilution together; if AI capex holds, MRVL’s concentrated data-center exposure can support recovery, but unchanged earnings estimates do not yet validate the expanded valuation.

Key Decisions for Investors

• Avoid chasing MRVL solely on the drawdown. Keep exposure sized to tolerate further multiple compression; reassess after definitive deal terms and pro forma share-count/accretion disclosures.
• For a relative-value expression, consider a modest long AVGO / short MRVL pair rather than a standalone MRVL short: the thesis is lower near-term integration and dilution uncertainty at AVGO. Revisit if MRVL sustains data-center guidance and demonstrates improving profitability through the deal process.
• Track MRVL gross margin and operating leverage alongside data-center growth. If growth accelerates but profitability deteriorates, the portfolio expansion is not translating into shareholder value; stronger margins and raised estimates would falsify the cautious view.
• Watch LITE’s exchange-ratio value and closing/regulatory milestones, plus evidence of customer retention and cross-selling. A delayed or revised transaction, or signs customers are avoiding bundled offerings, would weaken the strategic case and could pressure MRVL and LITE.